To determine if Alvimopan during open or robotic radical cystectomy with urinary
diversion results in quicker return of bowel function (GI-2 recovery = time to upper
[first toleration of solid food] and lower [first bowel movement] gastrointestinal
recovery) compared to placebo.
Additional locations may be listed on ClinicalTrials.gov for NCT03216525.
See trial information on ClinicalTrials.gov for a list of participating sites.
A prospective, randomized, single-center double blind trial of Alvimopan versus placebo
for improving patient outcomes and cost during radical cystectomy and urinary diversion
will be performed. A randomized trial is necessary to control for all the known and
unknown confounders associated with instituting this novel intervention into a surgical
procedure. We will recruit 136 subjects (63 patients in each arm of the study per sample
size calculation below, plus additional 10 subjects to account for drop outs). A control
group will be administered a placebo in order to directly compare if the Alvimopan
intervention is effective.
Lead OrganizationBrigham and Women's Hospital
Principal InvestigatorMark A Preston